Troponin I

• 

  Subject Areas on Research

  • A comprehensive guide to genetic variants and post-translational modifications of cardiac troponin C. 
  • A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. 
  • Adhesion molecules, platelet activation, and cardiovascular risk. 
  • Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study. 
  • Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. 
  • Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. 
  • Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. 
  • Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. 
  • Biomarker-based risk prediction in the community. 
  • Biomarkers in atrial fibrillation: a clinical review. 
  • Biomarkers in cardiovascular clinical trials: past, present, future. 
  • Cardiac Troponin I-Interacting Kinase Affects Cardiomyocyte S-Phase Activity but Not Cardiomyocyte Proliferation. 
  • Cardiac markers: point of care testing. 
  • Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Cardiac troponin T and I, echocardiographic [correction of electrocardiographic] wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. 
  • Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. 
  • Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. 
  • Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. 
  • Cardiac troponin release following hybrid coronary revascularization versus off-pump coronary artery bypass surgery. 
  • Cardiac troponins in congestive heart failure. 
  • Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Combination of Goldman risk and initial cardiac troponin I for emergency department chest pain patient risk stratification. 
  • Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. 
  • Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. 
  • Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). 
  • Copeptin to rule out myocardial infarction in Blacks versus Caucasians. 
  • Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. 
  • Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. 
  • Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. 
  • Do cardiac troponins provide prognostic insight in hemodialysis patients? 
  • Drosophila as a model for the identification of genes causing adult human heart disease. 
  • Effect of a Triage-Based Screening Protocol on Diagnosis and Treatment of Acute Coronary Syndrome in a Tanzanian Emergency Department: A Prospective Pre-Post Study. 
  • Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. 
  • Elevated Cardiac Troponin I in Preservation Solution Is Associated With Primary Graft Dysfunction. 
  • Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. 
  • G alpha(q)-coupled receptors in human atrium function through protein kinase C epsilon and delta. 
  • Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. 
  • High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial. 
  • High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. 
  • High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. 
  • Ideal high sensitivity troponin baseline cutoff for patients with renal dysfunction. 
  • Implications of High-Sensitivity Troponin Testing: Learning From Those Who Came Before Us. 
  • Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. 
  • Influence of imprecision on ROC curve analysis for cardiac markers. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome. 
  • Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. 
  • Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. 
  • Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). 
  • Meta-analysis of cardiomyopathy-associated variants in troponin genes identifies loci and intragenic hot spots that are associated with worse clinical outcomes. 
  • Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC consensus conference. European Society of Cardiology and American College of Cardiology. 
  • Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up. 
  • Multiple-analyte fluoroimmunoassay using an integrated optical waveguide sensor. 
  • Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. 
  • Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I. 
  • Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. 
  • Necessity of hospitalization and stress testing in low risk chest pain patients. 
  • Outpatient versus observation/inpatient management of emergency department patients rapidly ruled-out for acute myocardial infarction: Findings from the HIGH-US study. 
  • Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices. 
  • Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. 
  • Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. 
  • Pivotal findings for a high-sensitivity cardiac troponin assay: Results of the HIGH-US study. 
  • Platelet PlA2 polymorphism and platelet activation are associated with increased troponin I release after cardiopulmonary bypass. 
  • Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. 
  • Preliminary report on cardiac dysfunction after isolated traumatic brain injury. 
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. 
  • Prognosis is worse with elevated cardiac troponin in nonacute coronary syndrome compared with acute coronary syndrome. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. 
  • Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). 
  • Radiographic and Clinical Predictors of Cardiac Dysfunction Following Isolated Traumatic Brain Injury. 
  • Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). 
  • Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). 
  • Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. 
  • Relation of level of B-type natriuretic peptide with outcomes in patients with infective endocarditis. 
  • Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. 
  • Reply: hs-cTnI in Stable Chest Pain. 
  • Sensitive troponin I assay in patients with suspected acute coronary syndrome. 
  • Serum Troponin Level in Acute Ischemic Stroke Identifies Patients with Visceral Infarcts. 
  • Sexually dimorphic myofilament function and cardiac troponin I phosphospecies distribution in hypertrophic cardiomyopathy mice. 
  • Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The emerging role of myoglobin for risk stratification. 
  • The troponin I: inhibitory peptide uncouples force generation and the cooperativity of contractile activation in mammalian skeletal muscle. 
  • The utility of gestures in patients with chest discomfort. 
  • Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data). 
  • Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. 
  • Tissue-Engineered Human Myobundle System as a Platform for Evaluation of Skeletal Muscle Injury Biomarkers. 
  • Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. 
  • Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. 
  • Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. 
  • Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. 
  • Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. 
  • Troponin I in cardiac surgery: marking the future. 
  • Troponin and other cardiac markers: role in management of acute coronary syndromes. 
  • Troponins in pericarditis: implications for diagnosis and management of chest pains patients. 
  • Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Utility of High-Sensitivity Troponin Among Stable Patients With Chest Pain Undergoing Stress Imaging (from PROMISE). 
  • Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. 
  • p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. 
  • p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Limkakeng Jr., Alexander Tan, Professor of Emergency Medicine, Emergency Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology